Healthcare
Enhabit, Inc.(EHAB)
Live Price
Offline$13.80
+0.07% today
Window Change
+46.81%
Window
Jun 25, 2025 โ May 14, 2026
- Market Cap
- $700.00M
- Revenue Growth
- +2.4%
- EPS Growth
- +97.1%
- Dividend Yield
- 0.0%
Coverage: 224 bars ยท Jun 25, 2025 โ May 14, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Enhabit, Inc. (EHAB) is a Healthcare stock with a market cap of $700.00M and listed on NYSE. The stock last traded around $13.80 and up 46.8% across the available one-year price window (Jun 25, 2025 โ May 14, 2026). Baseline metrics include revenue growth of +2.4%, EPS growth of +97.1%, a dividend yield of 0.0%. What stands out right now is revenue +2.4%, EPS +97.1%, free cash flow +38.8% with operating margin 6.0% and ROIC -2.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Stock Foundry combines EHAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.4% vs +7.6% peer median
Operating Margin
Below sector median
+6.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +2.4% and EPS at +97.1%, with operating margin around 6.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +0.0% | +0.1% | โ |
2026 Mar 4, 2026 | +0.0% | +0.0% | +0.1% | +2.6% |
2025 Nov 5, 2025 | +41.7% | -6.1% | -1.9% | +13.4% |
Benchmark Edge
EHAB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EHAB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EHAB Max Drawdown
-32.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EHAB and SPY.
Company Overview
Enhabit, Inc.
New York Stock Exchange
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
- Leadership
- Barbara Ann Jacobsmeyer
- IPO Date
- Jun 23, 2022
- Employees
- 10.6k
- Street Address
- 6688 N. Central Expressway
- Mailing
- Dallas, TX, 75206
- Region
- Dallas, TX, US
- Reporting Currency
- USD
- Investor Line
- 214-239-6500
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 13.4
- Price/Sales
- 0.7
- Price/Book
- 1.3
Growth
- Revenue
- +2.4%
- EPS
- +97.1%
- Free Cash Flow
- +38.8%
Profitability
- Gross Margin
- 46.9%
- Operating Margin
- 6.0%
- Net Margin
- -0.4%
- ROE
- -0.8%
- ROIC
- -2.0%
Balance Sheet
- Debt/Equity
- 0.94
- Current Ratio
- 1.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.